• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

0.9209 -0.0629 (-6.39%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 52,629
Open 0.9900
Bid (Size) 0.9027 (600)
Ask (Size) 1.430 (200)
Prev. Close 0.9838
Today's Range 0.9027 - 0.9957
52wk Range 0.8808 - 5.450
Shares Outstanding 45,484,310
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
What Cellectis (CLLS) Said on Its Q3 Earnings Call ↗
November 13, 2026
Cellectis (NASDAQ:CLLS) said its cash runway is expected to extend into the second half of 2028 once its planned restructuring is fully implemented, giving the gene editing company time to reach... 
Via MarketBeat
Topics Earnings
News headline image
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
November 12, 2026
From Cellectis Inc.
Via GlobeNewswire

Performance

52-Week Range 83.1% below 52-week high
0.9209
0.8852W Low 5.4552W High
1 Week 19.2% below 1-week high
0.901W Low 1.141W High

Cellectis S.A. - American Depositary Shares (CLLS) traded between $0.88 and $5.45 over the past 52 weeks and last traded at $0.92, 83.1% below its 52-week high. Over the past week it ranged between $0.90 and $1.14.

Past 12 Months
-11.5%
-5.5%
-71.1%
-74.9%
-80.8%
-80.4%
1W -$0.12
1M -$0.05
3M -$2.27
6M -$2.75
YTD -$3.88
1Y -$3.77

CLLS was -80.4% over the past year, -74.9% over six months, -80.8% year to date, -11.5% in the last week.

12 Months vs Market
CLLS
-80.4%
DIA
+4.0%
SPY
+4.7%
QQQ
+3.1%
IWM
+8.9%

Over the past 12 months CLLS returned -80.4% versus DIA (Dow) +4.0%, SPY (S&P 500) +4.7%, QQQ (Nasdaq 100) +3.1% and IWM (Russell 2000) +8.9%.

Volume & Liquidity 0.46× 3-mo avg
Today 52,629 3-mo avg 115.1K
1W
40.0K
1M
66.3K
3M
115.1K
6M
73.4K
YTD
59.0K
1Y
65.5K

CLLS most recently traded 52,629 shares against a 3-month average daily volume of 115.1K.

More News

Read More
News headline image
Cellectis to Report Third Quarter Financial Results on November 12, 2026
November 09, 2026
From Cellectis Inc.
Via GlobeNewswire
Oct. 28 Gap Stocks: Double-Digit Gap-Up and Gap-Down Movers ↗
October 28, 2026
Via Chartmill
News headline image
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
October 27, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
October 20, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
October 13, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
October 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders ↗
October 01, 2026
Via MarketBeat
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
September 29, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
September 22, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
September 19, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
September 17, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
September 17, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
September 16, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
September 14, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
September 11, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Participation in Upcoming Investor Conferences
September 01, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Financial Results for the Second Quarter 2026
August 06, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report Second Quarter Financial Results on August 6, 2026
July 30, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
July 15, 2026
From ProLynx Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
June 25, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
June 11, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
June 09, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
May 21, 2026
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance

Frequently Asked Questions

Is Cellectis S.A. - American Depositary Shares publicly traded?
Yes, Cellectis S.A. - American Depositary Shares is publicly traded.
What exchange does Cellectis S.A. - American Depositary Shares trade on?
Cellectis S.A. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Cellectis S.A. - American Depositary Shares?
The ticker symbol for Cellectis S.A. - American Depositary Shares is CLLS on the Nasdaq Stock Market
What is the current price of Cellectis S.A. - American Depositary Shares?
The current price of Cellectis S.A. - American Depositary Shares is 0.9209
When was Cellectis S.A. - American Depositary Shares last traded?
The last trade of Cellectis S.A. - American Depositary Shares was at 11/20/26 04:00 PM ET
What is the market capitalization of Cellectis S.A. - American Depositary Shares?
The market capitalization of Cellectis S.A. - American Depositary Shares is 41.89M
How many shares of Cellectis S.A. - American Depositary Shares are outstanding?
Cellectis S.A. - American Depositary Shares has 42M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap